$79 Million

BELLUS Health, Inc.

Initial Public Offering

Bookrunner, September 2019

BELLUS Health, Inc.
BELLUS Health is a clinical stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cough and other chronic hypersensitization disorders. The company’s product candidate, BLU-5937, is a twice daily oral small molecule that is specifically designed to be a highly selective inhibitor of the P2X3 receptor, a clinically validated target linked to hypersensitivity.